CClinicalTrials.gg
Status unknownNCT03347812Updated Dec 27, 2017

Clinical Study for Evaluating the Safety and Efficacy of Total Endovascular Aortic Arch Repair

An observational study in Aortic Dissection, Aortic Arch Aneurysm and Ulcer, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Status unknown at 4 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-12-27.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
40 Years to 75 Years
Sex
All
01

Study summary

Aortic disease is a kind of cardiovascular diseases with very high mortality rate and high risk of surgical treatment. At present, the surgical and endovascular treatment for diseases in the ascending aorta, descending aorta and abdominal aorta are becoming more and more mature. However, due to the complexity of the aortic arch in anatomy, function and pathological changes, the optimal treatment strategy for diseases in the aortic arch has been controversial constantly.

This research is a multi-center(four centers), prospective, controlled, large-scale (about 400 subjects) clinical study, using traditional thoracic surgery of aortic arch disease as a control to verify that new techniques for endovascular treatment is not inferior to traditional thoracic surgery in terms of efficiency and safety.

Further more, the investigators plan to explore the indications of the application of these new techniques, develop a better diagnosis and treatment program, reduce the risk of such surgical treatment and the incidence of complications, improve clinical efficacy and the overall quality of the disease.

Read the detailed description

The subjects in this study are patients with aortic arch disease, after scientific assessment made by the team with wide experience in aortic open surgery and endovascular treatment, who are able to both withstand traditional total aortic arch replacement (TAR) and are suitable for complete thoracic endovascular aortic repair (cTEVAR) in terms of anatomical structure. According to the requirement of statistical analysis, more than 400 patients would be enrolled in the four centers (Fuwai Hospital, Peking University People's Hospital, China-Japan Friendship Hospital and Beijing Hospital) within 2 years. Combined the actual situation of the patients, subjects would be divided into TAR and cTEVAR groups. During the study, the investigators would collect the data including blood and biochemical indexes, complications, aortic CT examination, surgical procedure, and the follow-up information in discharge, one month after surgery, six months after surgery and twelve months after surgery.

The primary endpoint of this study is one-year treatment success, which means there are no death within 30 days after surgery, no adverse cardiovascular and no cerebrovascular events and no re-operative intervention associated with aorta occurred during the 1-year follow-up period. Secondary endpoints include the occurrence of postoperative leaks, occlusion, stenosis and thrombosis of aortic arch branches, the incidence of device-related adverse events, and the incidence of other serious complications. This study uses the primary endpoint as a measure of efficacy, and the secondary endpoint as a measure of safety for both treatment methods. The primary analysis of collected data would be based on intention-to-treat (ITT) principle, and all enrolled patients would be included in the final analysis.

The Cochran-Mantel-Haenszel (CMH) chi square analysis for adjusting center effects will be used for comparisons of major indicators, estimating differences in success rates and their 95% confidence intervals in two groups. If the lower limit of the 95% Confidence Interval (CI) of the difference in success rate between the test group and control group exceeds the pre-established non-inferiority cutoff, the endovascular treatment can be considered to be as effective as traditional open surgery. The significance level for all statistical tests is 5%, and the statistical analysis software is Statistics Analysis System (SAS) 9.3.

02

Conditions studied

  • Aortic Dissection
  • Aortic Arch Aneurysm
  • Ulcer
  • Pseudoaneurysm

Keywords

  • Aortic Arch
  • Endovascular Treatment
  • Traditional Open Surgery
  • Chimney Technique
  • Fenestration Technique
  • Branched Stent-grafts Technique
03

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients had aortic arch lesions, need surgery, and are hospitalized in these four hospitals (Fuwai Hospital, Beijing Hospital, China-Japan Friendship Hospital and Peking University People's Hospital) . These four hospitals are all located in Beijing, China.

Inclusion criteria

  • Patients have aortic arch lesions caused by atherosclerosis and hypertension, and are also suitable for both chimney/ fenestration / branch stent-grafts technique and total arch replacement surgery simultaneously.
  • Lesions involve the aortic arch, at least one branch of the aortic arch to be revascularized.
  • The type of lesion is dissection, aneurysm, pseudoaneurysm, or ulcer.
  • Life expectancy is more than 1 year.
  • Patients are able to understand the purpose of this trial, voluntarily attend and sign the informed consent form, and are willing to accept the specified follow-up at specific time point.

Exclusion criteria

Exclusion Criteria:

  • Patients had a stroke or ST-segment elevation myocardial infarction within 30 days prior to surgery.
  • Patients underwent major surgery (grade 3 or above) or interventional therapy within 30 days prior to surgery.
  • Patients will undergo any major elective surgery (grade 3 or above) or interventional therapy within 30 days after surgery.
  • Patients had a previous thoracic aortic surgery in the past.
  • Patients had previous thoracic aortic endovascular treatment, and the last implants had an effect on this procedure or had intersections with implants would be used in this procedure.
  • Patients need intervention in other vascular lesions (such as coronary arteries, lower extremity arteries, carotid arteries) in the same procedure, or have heart disease and postoperative medication regimens are affected.
  • Patients have hepatic and renal insufficiency (serum creatinine> 186umol / L, Child-Pugh grade B, grade C).
  • Aortic arch lesions are not caused by atherosclerosis or hypertension, such as connective tissue disease, aortic genetic diseases, etc.
  • Aortic arch lesions are caused by Infectious diseases.
  • Patients had serious illnesses (eg, severe chronic obstructive pulmonary disease (COPD) , cancer, dementia, etc.), or the physical condition would affect patients' compliance in this study.
  • Patients are currently participating in other studies, and the primary endpoint has not been reached.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Endovascular Aortic Repair

    Patients with aortic arch lesions who only received endovascular treatment, including chimney / fenestration / branch stent-grafts technique and combination of these techniques, would be assigned to this group.

    Procedure: Endovascular Aortic Repair

  • Total Arch Replacement

    Patients with aortic arch lesions who only received traditional open surgery for total aortic arch replacement, would be assigned to this group.

    Procedure: Total Arch Replacement

Interventions

  • ProcedureEndovascular Aortic Repair

    Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.

  • ProcedureTotal Arch Replacement

    A kind of open surgery is performed for the replacement of total aortic arch.

05

What researchers measure

Primary outcomes

  1. No death within 30 days after surgery

    Death from all causes would be included.

    Time frame: 1 month after surgery for treating aortic arch disease performed

  2. No adverse cardiovascular and cerebrovascular events within one year after surgery

    Cerebrovascular adverse events include global neurological deficit, focal neurological deficit and spinal neurological deficit. Cardiovascular adverse events include extensive myocardial ischemia, low cardiac output syndrome, malignant arrhythmia and massive pericardial effusion.

    Time frame: 12 month after surgery for treating aortic arch disease performed

  3. No reoperative intervention associated with aorta occurred within one year after surgery

    Reoperative intervention associated with aorta means unintended open or endovascular treatment of the aortic disease, excluding non-aortic surgery.

    Time frame: 12 month after surgery

Secondary outcomes

  1. Postoperative leakage

    Leakage is divided into five types according to the eighth edition of Rutherford Vascular Surgery.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 6 month and 12 month after surgery for treating aortic arch disease performed

  2. Patency rate of aortic arch branches

    The patency of aortic arch branches (anonymous artery, left carotid artery, left subclavian artery), and whether occlusion, stenosis, thrombosis occurring in branches.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 6 month and 12 month after surgery for treating aortic arch disease performed

  3. Device-related adverse events occurred

    Device-related adverse events include stent unable deploy and / or relaying to surgery, the dissection, thrombus, hematoma, pseudoaneurysm or infection of the access artery, unexplained fever continued for more than month, device-induced aortic dissection rupture or tear, displacement, infection, fracture of stent-grafts.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 1 month, 6 month and 12 month after surgery for treating aortic arch disease performed

  4. Postoperative new pulmonary infections

    New pulmonary infections occurred within 30 days after surgery.

    Time frame: 30 days after surgery for treating aortic arch disease performed.

  5. Hypostatic pneumonia

    Long-term bed rest caused chronic congestion in the bottom of the lungs.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 1 month, 6 month and 12 month after surgery for treating aortic arch disease performed

  6. Lower extremity deep vein thrombosis

    It refers to the coagulation of venous blood in deep veins of the lower extremities.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 1 month, 6 month and 12 month after surgery for treating aortic arch disease performed

  7. Pulmonary embolism

    Endogenous or exogenous embolus clogged the main pulmonary artery or branch, causing pulmonary circulatory disorders.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 1 month, 6 month and 12 month after surgery for treating aortic arch disease performed

  8. Wound infection

    Wounds occurred postoperative infection.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 1 month, 6 month and 12 month after surgery for treating aortic arch disease performed

  9. Liver dysfunction

    Child-pugh's Grade of patient is B or C grade.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 1 month, 6 month and 12 month after surgery for treating aortic arch disease performed

  10. Renal dysfunction

    Serum creatinine is more than 186umol/L.

    Time frame: When patient is discharged from hospital after surgery for treating aortic arch disease performed, 1 month, 6 month and 12 month after surgery for treating aortic arch disease performed

Other outcomes

  1. Extremities blood pressure measurement

    Blood pressure of left upper limb, right upper limb, left lower limb, right lower limb

    Time frame: 3 days before the surgery for treating aortic arch disease performed, 5 days after surgery for treating aortic arch disease performed

06

Study locations

1 of 4 sites recruiting
  • Beijing Hospital
    Beijing, Beijing 100000, China
    • Qian Zhou · Contact · 010-58115036
    Not yet recruiting
  • Chian-Japan Friendship Hospital
    Beijing, Beijing 100000, China
    • Yong Cui · Contact · 010-84205147
    Not yet recruiting
  • Chinese Academy of Medical Sciences, Fuwai Hospital
    Beijing, Beijing 100000, China
    Recruiting
  • Peking University People's Hospital
    Beijing, Beijing 100000, China
    • Tao Xu · Contact · 010-88325911
    Not yet recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03347812
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborators
Peking University People's Hospital, China-Japan Friendship Hospital, Beijing Hospital
Responsible party
Chang Shu (Director of Vascular Surgery Center, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Nov 20, 2017
Start date
Nov 22, 2017
Primary completion
Mar 2020 (estimated)
Completion
Mar 2020 (estimated)
Last update
Dec 27, 2017

Study contacts

Mingyao Luo, Physician
Contact
luomingyao@hotmail.com
+86 17701022238
Kun Fang, Physician
Contact
frankinxy@hotmail.com
+86 15201120100
Chang Shu, Director
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion